Vanguard Group Inc Akero Therapeutics, Inc. Transaction History
Vanguard Group Inc
- $5.37 Trillion
- Q1 2025
A detailed history of Vanguard Group Inc transactions in Akero Therapeutics, Inc. stock. As of the latest transaction made, Vanguard Group Inc holds 4,230,644 shares of AKRO stock, worth $204 Million. This represents 0.0% of its overall portfolio holdings.
Number of Shares
4,230,644
Previous 3,704,411
14.21%
Holding current value
$204 Million
Previous $103 Million
66.18%
% of portfolio
0.0%
Previous 0.0%
Shares
16 transactions
Others Institutions Holding AKRO
# of Institutions
270Shares Held
86MCall Options Held
1.02MPut Options Held
823K-
Rtw Investments, LP New York, NY7.42MShares$358 Million4.92% of portfolio
-
Janus Henderson Group PLC London, X07.07MShares$341 Million0.16% of portfolio
-
Wellington Management Group LLP Boston, MA5.94MShares$286 Million0.05% of portfolio
-
Black Rock Inc. New York, NY5.59MShares$269 Million0.0% of portfolio
-
General Atlantic LLC New York, NY5.23MShares$252 Million7.15% of portfolio
About Akero Therapeutics, Inc.
- Ticker AKRO
- Exchange NASDAQ
- Sector Healthcare
- Industry Biotechnology
- Shares Outstandng 46,417,600
- Market Cap $2.24B
- Description
- Akero Therapeutics, Inc., a cardio-metabolic nonalcoholic steatohepatitis (NASH) company, engages in the development of medicines designed to restore metabolic balance and improve overall health. The company's lead product candidate is efruxifermin (EFX), an analog of fibroblast growth factor 21, which protects against cellular stress and regula...